IBR-822

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug NameIBR-822

Drug Alias NameIBR822IBR-822

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > ACC-NKCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived

Mechanisms of ActionAnti-Trop-2

TargetsTumor-associated calcium signal transducer 2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesImbioray (Hangzhou) Biomedicine Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImbioray (Hangzhou) Biomedicine Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A